XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
SEGMENT AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, cranial stabilization equipment, and solutions for use in minimally invasive neurosurgery and in the management of intracerebral hemorrhages, and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
•The Tissue Technologies segment includes a large, complementary portfolio of products to address plastic and surgical reconstructive procedures such as complex and traumatic wounds, hernia and abdominal wall repair, breast reconstruction, and peripheral nerve repair. The Tissue Technologies segment has four unique technology platforms, including bovine engineered collagen matrix, bovine dermal matrix, amniotic technology and porcine bladder matrix technology, to address regenerative soft tissue reconstruction procedures.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three and nine months ended September 30, 2022 and 2021 are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2022202120222021
Segment Net Sales
Codman Specialty Surgical$249,796 $256,497 $754,967 $754,575 
Tissue Technologies
135,395 130,364 404,677 382,349 
Total revenues$385,191 $386,861 $1,159,644 $1,136,924 
Segment Profit
Codman Specialty Surgical$105,717 $110,686 $308,073 $331,460 
Tissue Technologies
59,754 57,730 175,273172,154 
Segment profit165,471 168,416 483,346 503,614 
Amortization(3,141)(4,113)(10,339)(12,838)
Corporate and other(97,281)(107,864)(301,927)(351,769)
Operating income$65,049 $56,439 $171,080 $139,007 
The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in thousands2022202120222021
United States$282,016 $275,775 $832,714 $801,754 
Europe38,301 46,458 128,907 140,714 
Asia Pacific42,774 45,015 133,856 136,616 
Rest of World22,100 19,613 64,167 57,840 
Total Revenues$385,191 $386,861 $1,159,644 $1,136,924